Though the top prize eluded the field, 10 pharma companies racked up gold, silver or bronze Lions for their marketing and advertising efforts.
With impressive new survival data in hand, Bristol-Myers Squibb and AbbVie could land a new indication for Empliciti.
Wells Fargo analyst depicted the rejection as “a major setback” for Valeant that puts a dent in the company’s five-year growth plan.
Some investors supported resolutions asking for more info about the link between drug prices and executive pay.
Another week, another dismal pharma trust and reputation poll. This time, the poll comes from the Reputation Institute.
Allergan is keeping the birth control questions coming—this time in a quiz format.
Dr. Reddy's moved ahead with an "at risk" launch of Indivior's top drug, but now a court has put the rollout on hold.
CANNES, France—Pharma keys in on opportunities to scout talent, show creative work and win awards at 2018 Cannes Lions Health.
Celltrion says its biosimilars for Herceptin and Rituxan could be approved this year after it made plant improvements to resolve and FDA warning letter.
Outcome Health tapped Publicis veteran Matt McNally to take the helm as it steers past a year of media and legal turmoil.
.jpg?c1l3t3ARuKj1I7r1C1plIJwVRI23EvSi&itok=9_ApMU4b)
.jpeg/original (1).jpeg?aOojEvV8LY5Cgs34qog1Lu_q9iOUS3LZ&itok=5aD_Uv-N "Bristol-Myers Squibb")
